- Home
- RRGB vs TCRX Comparison
RRGB vs TCRX Comparison
Compare RRGB & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- TCRX
- Stock Information
- Founded
- RRGB 1969
- TCRX 2018
- Country
- RRGB United States
- TCRX United States
- Employees
- RRGB N/A
- TCRX N/A
- Industry
- RRGB Restaurants
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- TCRX Health Care
- Exchange
- RRGB Nasdaq
- TCRX Nasdaq
- Market Cap
- RRGB 88.7M
- TCRX 82.1M
- IPO Year
- RRGB 2002
- TCRX 2021
- Fundamental
- Price
- RRGB $6.79
- TCRX $1.93
- Analyst Decision
- RRGB Strong Buy
- TCRX Strong Buy
- Analyst Count
- RRGB 4
- TCRX 6
- Target Price
- RRGB $12.38
- TCRX $9.50
- AVG Volume (30 Days)
- RRGB 318.3K
- TCRX 574.8K
- Earning Date
- RRGB 08-21-2025
- TCRX 08-11-2025
- Dividend Yield
- RRGB N/A
- TCRX N/A
- EPS Growth
- RRGB N/A
- TCRX N/A
- EPS
- RRGB N/A
- TCRX N/A
- Revenue
- RRGB $1,252,370,000.00
- TCRX $4,421,000.00
- Revenue This Year
- RRGB N/A
- TCRX $159.20
- Revenue Next Year
- RRGB N/A
- TCRX N/A
- P/E Ratio
- RRGB N/A
- TCRX N/A
- Revenue Growth
- RRGB N/A
- TCRX N/A
- 52 Week Low
- RRGB $2.50
- TCRX $1.02
- 52 Week High
- RRGB $7.89
- TCRX $7.44
- Technical
- Relative Strength Index (RSI)
- RRGB 59.21
- TCRX 63.03
- Support Level
- RRGB $6.77
- TCRX $1.75
- Resistance Level
- RRGB $7.89
- TCRX $1.96
- Average True Range (ATR)
- RRGB 0.44
- TCRX 0.14
- MACD
- RRGB 0.03
- TCRX 0.01
- Stochastic Oscillator
- RRGB 51.54
- TCRX 94.00
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.